Compare Stocks

Stifel lowered the firm’s price target on Geron (GERN) to $3.50 from $4 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source for

Geron Corporation (GERN) is scheduled to report 3rd quarter earnings on 11/04/2026, before the market opens. Regarding Q3 estimates, Wall Street analysts expect Geron Corporation to post earnings of -$0.01

Wedbush lowered the firm’s price target on Geron (GERN) to $5 from $6 and keeps an Outperform rating on the shares. The firm notes the company announced the discontinuation of

Geron ( ($GERN) ) has issued an announcement. On October 28, 2026, Geron Corporation said it would discontinue its Phase 3 IMpactMF clinical trial of imetelstat in patients with relapsed

Geron (GERN) announced the decision to discontinue the Phase 3 IMpactMF trial evaluating imetelstat in JAK inhibitor relapsed/refractory myelofibrosis. This decision was based on a recommendation from the independent Data

A federal judge in California has denied the defendant’s motion to dismiss an investor lawsuit alleging that the company and certain executives made false or misleading statements about Rytelo’s commercial

Geron Corporation (($GERN)) has held its Q2 earnings call. Read on for the main highlights of the call. Geron’s latest earnings call struck a broadly upbeat tone as management highlighted

Unusual total active option classes on open include: Geron (GERN), AstraZeneca (AZN), Shopify (SHOP), PG&E (PCG), Fluence Energy (FLNC), Beyond Meat (BYND), Target (TGT), AGNC Investment Corp. (AGNC), Disney (DIS),

Reports Q2 revenue $57.48M, consensus $55.38M. “We are executing a focused strategy to build a leading hematology company, which starts with bringing RYTELO to more eligible patients impacted by LR-MDS

The company said, “For fiscal year 2026, the Company expects RYTELO net product revenue to be in the range of $220 million to $240 million. Geron (GERN) also expects total